BioLife Solutions (BLFS) Q3 2024: Cell Processing Revenue Jumps 43% as SciSafe Exit Sharpens Focus
BioLife Solutions delivered its fourth straight quarter of sequential revenue growth, fueled by a 43% surge in cell processing and a strategic pivot away from biostorage. The SciSafe divestiture marks a decisive move toward a pure-play, high-margin CGT tools model, with management signaling further margin gains and disciplined capital allocation ahead. Investors should watch for continued expansion in biopreservation media and execution on the streamlined, recurring-revenue strategy as the company enters 2025.
Summary
- Margin Expansion Accelerates: High-margin cell processing drives profitability as the company exits lower-margin storage.
- Strategic Portfolio Streamlining: SciSafe divestiture and CBS exit signal a focused push into proprietary CGT tools.
- 2025 Growth Levers Solidify: Biopreservation media adoption and new product launches underpin forward revenue visibility.
Business Overview
BioLife Solutions develops and sells biopreservation media, cell processing tools, and related products for the cell and gene therapy (CGT) market. The company generates revenue primarily from its cell processing platform, which supplies high-margin, recurring consumables to biopharma, CDMO (contract development and manufacturing organization), and academic customers. Until Q3, BioLife also operated a biostorage segment (SciSafe) and a freezer business (CBS), both of which are being divested to concentrate resources on proprietary, high-growth cell processing and reagents.
Performance Analysis
BioLife posted a 30% year-over-year revenue increase from continuing operations, with cell processing revenue up 43% and now representing the dominant growth engine. The biopreservation media line, which accounts for the majority of cell processing sales, saw strong demand across its top 20 customers, who collectively generate about 80% of media revenue. This customer concentration is a double-edged sword, amplifying the impact of top client wins but also exposing the company to risk if key accounts stumble.
Gross margin expanded to 54% (adjusted), up sharply from 44% a year ago, reflecting the shift toward higher-margin consumables and improved facility utilization. Adjusted EBITDA margin reached 20%, tripling year-over-year, as operating expenses fell on lower headcount and reduced asset impairment charges. The SciSafe biostorage business contributed $16 million in year-to-date revenue but was deemed non-core, with the recent $73 million all-cash sale expected to further enhance the company’s margin profile and balance sheet flexibility.
- Cell Processing Dominance: 43% YoY growth in cell processing drove overall top-line gains and margin improvement.
- Recurring Revenue Strength: Biopreservation media embedded in 17 approved therapies and over 70% of CGT clinical trials, supporting sustainable growth.
- Cost Discipline: Operating expenses declined meaningfully, reflecting headcount reductions and a focus on core profitability levers.
Sequential cash growth and a strengthened balance sheet position BioLife to invest in capacity and product development, while ongoing repayment of term debt remains manageable.
Executive Commentary
"This morning's announcement of the sale of our SciSafe biostorage business and a $73 million all-cash transaction is a pivotal step in the evolution of BioLife into a pure-play CGT tools provider, driven by our recurring reagents business. Not only does the divestiture fortify our balance sheet, it also frees up significant operational bandwidth, which will be redeployed to support the growth of our core cell processing products."
Roderick DeGrief, CEO and Chairman of the Board
"Although there was a slight decrease in our adjusted EBITDA profile for the first half of 2024 with OutsideSafe, we believe we will have a stronger EBITDA profile going forward with OutsideSafe as media revenue increases, which has a significant flow-through to our bottom line."
Troy Wicherman, Chief Financial Officer
Strategic Positioning
1. Pure-Play CGT Tools Focus
The SciSafe divestiture marks a clear pivot to a focused, high-margin CGT (cell and gene therapy) tools and reagents provider model. Management is committed to further exiting the CBS freezer business, reinforcing the intention to allocate all resources toward proprietary consumables and automation tools for cell processing.
2. Biopreservation Media as Core Growth Engine
Biopreservation media, recurring consumables used to preserve cell viability during storage and transport, is now the undisputed anchor of BioLife’s business. These products are embedded in 17 approved CGT therapies and over 70% of relevant clinical trials, providing high visibility into future revenue streams as new therapies are approved and usage expands geographically and by indication.
3. Margin Expansion and Operational Leverage
Margin gains are being driven by the mix shift to high-margin media, cost reductions from portfolio simplification, and improved facility utilization. Management targets gross margins in the upper 60% range, with adjusted EBITDA leverage expected to improve as scale and product mix continue to shift toward proprietary reagents.
4. Disciplined Capital Allocation and M&A
Proceeds from the SciSafe sale will be used to expand capacity in core media lines and potentially pursue highly selective M&A that directly strengthens market leadership in cell processing tools. Management emphasized that any inorganic moves must be margin-accretive and tightly aligned with core competencies.
5. Commercial Execution and Channel Optimization
Sales and marketing have been consolidated under a new Chief Commercial Officer, aiming for tighter alignment and improved cross-selling of new products like the CryoCase automated fill machine. Deeper distributor relationships and pricing optimization (reducing legacy discounts) are identified as levers for incremental growth, especially among smaller biopharma and academic customers.
Key Considerations
This quarter represents a turning point as BioLife transitions from a diversified life sciences supplier to a streamlined, high-margin CGT tools pure-play. The company’s ability to execute on this strategy will determine its long-term growth and margin trajectory.
Key Considerations:
- Customer Concentration Risk: 80% of media revenue comes from 20 customers, amplifying both opportunity and risk as client success directly impacts BioLife’s growth.
- Recurring Revenue Model: Proprietary reagents and consumables drive high visibility, but depend on continued CGT therapy approvals and clinical trial activity.
- Margin Expansion Potential: Mix shift away from services and hardware toward consumables could lift gross margins into the upper 60% range, per management’s target.
- Execution on Product Launches: Success of new offerings like CryoCase and cross-selling into the existing customer base will be key for incremental growth in 2025 and beyond.
- International Expansion: Current exposure to Asia is limited, reducing risk from geopolitical or regulatory shifts, but also capping near-term growth from that region.
Risks
BioLife’s concentrated customer base and reliance on the pace of CGT therapy approvals create exposure to biopharma market cycles and client-specific volatility. The transition away from legacy businesses like SciSafe and CBS, while margin-accretive, could temporarily disrupt revenue stability. Further, any delays in new product adoption or setbacks among top customers could impact growth and profitability, while macro or regulatory headwinds in CGT could slow clinical trial momentum.
Forward Outlook
For Q4 and FY 2024, BioLife guided to:
- Total revenue of $98 million to $100 million, reflecting an increase in cell processing guidance offset by the removal of SciSafe revenue.
- Cell processing platform revenue of $72 million to $73 million, representing 9% to 11% growth over 2023.
Management highlighted:
- Continued sequential growth in biopreservation media, with six additional therapy approvals or expansions expected in the next 12 months.
- Margin expansion as the product mix shifts further toward proprietary reagents and away from lower-margin storage and hardware.
Takeaways
- Portfolio Simplification Drives Margin: The sale of SciSafe and planned CBS exit sharpen BioLife’s focus on high-margin, recurring cell processing consumables, setting the stage for sustained profitability improvement.
- Growth Anchored in Biopreservation Media: Deep integration in CGT clinical trials and approved therapies provides a strong foundation for future revenue, with cross-selling and new product launches offering upside.
- Execution Remains Key: Investors should monitor progress on capacity expansion, customer diversification, and successful commercialization of new cell processing tools as the company enters 2025.
Conclusion
BioLife Solutions’ Q3 marks a strategic inflection point, with the company now executing as a focused, high-margin CGT tools provider. Margin expansion and recurring revenue strength underpin a bullish setup for 2025, but execution on product launches and customer diversification will be critical to sustaining the current growth trajectory.
Industry Read-Through
BioLife’s results highlight a broader shift among life sciences suppliers toward high-margin, recurring consumables and away from capital-intensive services or hardware. The company’s success in embedding its biopreservation media in a majority of CGT clinical trials underscores the increasing importance of specialized reagents in the cell and gene therapy ecosystem. The SciSafe divestiture and focus on core competencies may serve as a blueprint for other suppliers seeking to optimize margin and operational leverage. For the CGT tools segment, the pace of therapy approvals and clinical trial activity remains the key demand driver, while customer concentration and regulatory dynamics will continue to shape risk profiles across the industry.